Assess whether related-party sales should be backed out of valuation (1ef714)

SITUATION Regulatory-approval critical-path calendar arrived with an earnout based on 'adjusted EBITDA' with no dictionary for customer-contract risk reviewer. That is a M&A Due Diligence Legal, IP, and Regulatory decision on related-party sales should be in a family-office reviewing a manufacturing target.

DECISION Customer-contract risk reviewer in a family-office reviewing a manufacturing target must choose Proceed / Reprice / Walk / Hold using regulatory-approval critical-path calendar after an earnout based on 'adjusted EBITDA' with no dictionary.

HYPOTHESES TO TEST 1. Regulatory-approval critical-path calendar reads as Proceed once an earnout based on 'adjusted EBITDA' with no dictionary is lined up to the same M&A Due Diligence population. 2. Regulatory-approval critical-path calendar is closer to Reprice after an earnout based on 'adjusted EBITDA' with no dictionary; Proceed would over-claim this Legal, IP, and Regulatory extract. 3. Walk is still live in regulatory-approval critical-path calendar for customer-contract risk reviewer in a family-office reviewing a manufacturing target. 4. Regulatory-approval critical-path calendar is missing the fact customer-contract risk reviewer needs after an earnout based on 'adjusted EBITDA' with no dictionary; stop this M&A Due Diligence close.

ANALYSIS REQUIRED 1. Separate a one-off add-back from a recurring earnings issue in regulatory-approval critical-path calendar. 2. Map reps, earnout mechanics, and integration risk a family-office reviewing a manufacturing target would inherit. 3. Tie quality-of-earnings, working-capital, and contingent items in regulatory-approval critical-path calendar to related-party sales should be. 4. For this M&A Due Diligence Legal, IP, and Regulatory file, read regulatory-approval critical-path calendar against an earnout based on 'adjusted EBITDA' with no dictionary and write the one fact that would move related-party sales should be for customer-contract risk reviewer.

RECOMMENDATION Choose Proceed / Reprice / Walk / Hold on this M&A Due Diligence / Legal, IP, and Regulatory packet (regulatory-approval critical-path calendar after an earnout based on 'adjusted EBITDA' with no dictionary). Lead with the M&A Due Diligence option regulatory-approval critical-path calendar can support after an earnout based on 'adjusted EBITDA' with no dictionary, then the two facts that force it, then the Monday action for customer-contract risk reviewer in a family-office reviewing a manufacturing target.

COMMAND RETURNS - Bottom-line M&A Due Diligence option on related-party sales should be, then the evidence in regulatory-approval critical-path calendar, then the action for customer-contract risk reviewer - Hypothesis scorecard against regulatory-approval critical-path calendar: supported / rejected / untestable - Missing page in regulatory-approval critical-path calendar after an earnout based on 'adjusted EBITDA' with no dictionary, if any - Regulatory or exam hook Legal, IP, and Regulatory would cite